Zoetis (ZTS) Stock Forecast & Price Target

$71.24 -0.17 (-0.24%)

Closing price 03:59 PM Eastern

Extended Trading

$71.00 -0.24 (-0.34%)

As of 06:09 PM Eastern

Compare

Zoetis - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Hold

Based on 19 Analyst Ratings

Sell
2

Hold
9

Buy
8

Based on 19 Wall Street analysts who have issued ratings for Zoetis in the last 12 months, the stock has a consensus rating of "Hold." Out of the 19 analysts, 2 have given a sell rating, 9 have given a hold rating, and 8 have given a buy rating for ZTS.

Consensus Price Target

$101.08
41.88% Upside

According to the 19 analysts' twelve-month price targets for Zoetis, the average price target is $101.08. The highest price target for ZTS is $160.00, while the lowest price target for ZTS is $80.00. The average price target represents a forecasted upside of 41.88% from the current price of $71.24.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for ZTS and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Zoetis and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ZTS Analyst Ratings Over Time

Type	Current Forecast 10/6/25 to 10/6/26	1 Month Ago 9/6/25 to 9/6/26	3 Months Ago 7/8/25 to 7/8/26	1 Year Ago 10/6/24 to 10/6/25
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	8 Buy rating(s)	8 Buy rating(s)	8 Buy rating(s)	5 Buy rating(s)
Hold	9 Hold rating(s)	9 Hold rating(s)	8 Hold rating(s)	4 Hold rating(s)
Sell	2 Sell rating(s)	2 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$101.08	$107.43	$123.46	$200.88
Forecasted Upside	41.88% Upside	41.91% Upside	64.49% Upside	38.16% Upside
Consensus Rating	Hold	Hold	Hold	Moderate Buy

ZTS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ZTS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Zoetis Stock vs. The Competition

Type	Zoetis	Healthcare Companies	Broader Market
Consensus Rating Score	2.32	2.31	2.53
Consensus Rating	Hold	Hold	Moderate Buy
Predicted Upside	41.46% Upside	841.28% Upside	19.92% Upside
News Sentiment Rating	Neutral News See Recent ZTS News	Neutral News	Neutral News

Recent Analyst Forecasts and Stock Ratings

Show

Rating

Upside/Downside

Action

Report Date

0 Results

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
9/9/2026	Weiss Ratings 3 of 5 stars		Reiterated Rating	Sell (D)
8/25/2026	TD Cowen 3 of 5 stars	Steve Scala Not Rated	Lower Target	Buy	$104.00 ➝ $94.00	+21.87%
8/25/2026	Cantor Fitzgerald 5 of 5 stars		Set Target		$94.00	+21.87%
8/20/2026	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jonathan Block Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Hold	$85.00 ➝ $80.00	+4.19%
8/11/2026	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Daniel Grosslight Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$112.00 ➝ $96.00	+27.60%
8/11/2026	BNP Paribas Exane Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Navann Ty Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Outperform	$146.00 ➝ $110.00	+46.54%
8/10/2026	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Hold ➝ Strong Sell
8/10/2026	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Westenberg Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Neutral	$90.00 ➝ $80.00	+7.42%
8/7/2026	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Erin Wright Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target		$85.00	+14.19%
8/7/2026	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Andrea Alfonso Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Neutral	$85.00 ➝ $80.00	+10.30%
Get the Latest News and Ratings for ZTS and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Zoetis and its competitors with MarketBeat's FREE daily newsletter.
8/7/2026	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Chris Schott Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Overweight	$130.00 ➝ $115.00	+58.36%
8/6/2026	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Brandon Vazquez Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform
7/6/2026	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Rajesh Kumar Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$140.00 ➝ $95.00	+26.18%
7/1/2026	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Glen Santangelo Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Equal Weight	$136.00 ➝ $85.00	+18.25%
5/27/2026	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jasper Hellweg Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
3/10/2026	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Market Perform
2/26/2026	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mark Massaro Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy	$160.00	+23.89%
2/13/2026	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Michael Ryskin Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Neutral	$135.00 ➝ $140.00	+11.48%
12/15/2025	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Buy
11/20/2025	KeyCorp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Steve Dechert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Sector Weight

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 06:11 PM ET.

Should I Buy Zoetis Stock? ZTS Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, October 2, 2026. Please send any questions or comments about these Zoetis pros and cons to contact@marketbeat.com.

Zoetis
Bull Case

Here are some ways that investors could benefit from investing in Zoetis Inc.:

The stock is trading at $69.62, which is near its 52-week low of $68.77, offering a potential entry point for value-oriented investors who believe the market has overreacted to recent challenges.
With a price-to-earnings ratio of 11.47, Zoetis Inc. is trading at a significant discount compared to many of its pharmaceutical peers, suggesting the stock may be undervalued relative to its earnings power.
The company offers a dividend yield of 3.04%, providing a steady income stream for investors who prioritize cash flow over pure capital appreciation.
Recent insider activity shows confidence in the company's long-term prospects, with directors Paul Bisaro, Frank A. Damelio, and Michael B. Mccallister all purchasing shares in May 2026.
Zoetis Inc. maintains a strong balance sheet with a current ratio of 3.08 and a quick ratio of 1.84, indicating ample liquidity to manage operations and debt obligations.

Zoetis
Bear Case

Investors should be bearish about investing in Zoetis Inc. for these reasons:

The stock has experienced a significant decline, hitting a 52-week low of $68.77 in late September 2026, reflecting persistent downward pressure and a loss of momentum.
Analyst sentiment has deteriorated, with the consensus price target dropping from $152.91 in early 2026 to $101.08 as of October 2026, indicating a substantial reduction in expected future value.
Short interest has increased, with shares shorted rising to 17.39 million as of September 2026, suggesting that a growing number of traders are betting against the stock's performance.
Revenue growth has stalled, with the most recent quarter showing a year-over-year decline of 0.2%, signaling potential challenges in maintaining sales momentum in a competitive market.
The company faces intensified competition in key areas such as dermatology and parasiticides, which is pressuring sales and may limit future pricing power and market share.

ZTS Forecast - Frequently Asked Questions

According to the research reports of 19 Wall Street equities research analysts, the average twelve-month stock price forecast for Zoetis is $101.08, with a high forecast of $160.00 and a low forecast of $80.00.

19 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Zoetis in the last year. There are currently 2 sell ratings, 9 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ZTS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ZTS, but not buy additional shares or sell existing shares.

According to analysts, Zoetis's stock has a predicted upside of 41.88% based on their 12-month stock forecasts.

Over the previous 90 days, Zoetis's stock had 1 downgrade by analysts.

Zoetis has been rated by research analysts at BNP Paribas Exane, Cantor Fitzgerald, Citigroup, JPMorgan Chase & Co., Morgan Stanley, Piper Sandler, Stifel Nicolaus, TD Cowen, UBS Group, Weiss Ratings, William Blair, and Zacks Research in the past 90 days.

Analysts like Zoetis more than other "healthcare" companies. The consensus rating score for Zoetis is 2.32 while the average consensus rating score for "healthcare" companies is 2.31. Learn more on how ZTS compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Zoetis Recommendations

MarketBeat monitors more than a dozen sources for Zoetis analyst ratings, with the most recent rating issued on 9/9/2026.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Zoetis (ZTS) Stock Forecast & Price Target

Zoetis - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

ZTS Analyst Ratings Over Time

ZTS Analyst Recommendations By Month

ZTS Price Targets by Month

Zoetis Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy Zoetis Stock? ZTS Pros and Cons Explained

Zoetis
Bull Case

Zoetis
Bear Case

ZTS Forecast - Frequently Asked Questions

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Zoetis Recommendations

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Zoetis (ZTS) Stock Forecast & Price Target

Zoetis - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

ZTS Analyst Ratings Over Time

ZTS Analyst Recommendations By Month

ZTS Price Targets by Month

Zoetis Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy Zoetis Stock? ZTS Pros and Cons Explained

Zoetis Bull Case

Zoetis Bear Case

ZTS Forecast - Frequently Asked Questions

What is Zoetis' forecast for 2026?

Should I buy or sell Zoetis stock right now?

Does Zoetis's stock price have much upside?

Has Zoetis been downgraded by Wall Street analysts recently?

What analysts cover Zoetis?

Do Wall Street analysts like Zoetis more than its competitors?

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Zoetis Recommendations

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

Zoetis
Bull Case

Zoetis
Bear Case